Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.

ABSTRACT:

Background

The individual risk of recurrence in hormone receptor-positive primary breast cancer patients determines whether adjuvant endocrine therapy should be combined with chemotherapy. Clinicopathological parameters and molecular tests such as EndoPredict(®) (EPclin) can support decision making in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative cancer.

Objective

Using a life-long Markov state transition model, we determined the health economic impact and incremental cost effectiveness of EPclin-based risk stratification in combination with clinical guidelines [German-S3, National Comprehensive Cancer Center Network (NCCN), and St. Gallen] to decide on chemotherapy use.

Methods

Information on overall and metastasis

SUBMITTER: Blank PR 

PROVIDER: S-EPMC4305105 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature